Telix gains attention after FDA clears Pixclara as CSL rallies 31% to A$176.50
AI Market Summary
An ASX biotech rotation narrative highlights CSL's sharp rebound despite impairment-driven FY26 losses and analyst targets implying limited upside after the rally. The more material catalyst is Telix's FDA approval of Pixclara, expanding its radiopharmaceutical imaging franchise and reinforcing pipeline optionality alongside strong 1H FY26 margin and EBITDA momentum. Near-term impact is likely concentrated in ASX healthcare/biotech sentiment rather than broader macro markets.
Impact level
● Low
Affected assets
NCSKASX2USD/USDT+3.30%
AI Insight · NCSKASX2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
CSL shares have rebounded about 31% over the past month to A$176.50, but the A$159.86 average target price implies around 8% downside. The company reported FY26 revenue of US$15.8 billion and NPAT of US$2.6 billion, while also booking a net loss after tax of US$2.6 billion driven by impairments and restructuring costs. Management described FY26 as a “reset year” and said FY27 should mark a return to growth, while adjusted EBITDA rose 146% year on year to US$52 million.
